INSTIL BIO INC (TIL)
US45783C2008 - Common Stock
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
This drugmaker's lead candidate could become a top-selling cancer therapy.
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
These relatively small companies are developing new cancer therapies that could generate billions in annual sales.
Here's Why Everyone's Talking About Summit Therapeutics
Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
Global registrational strategy in first-line non-squamous and squamous non-small cell lung cancer (NSCLC)Global registrational strategy in first-line...
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy.
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2024
TIL stock results show that Instil Bio beat analyst estimates for earnings per share the second quarter of 2024.
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Instil Bio (NASDAQ:TIL) just reported results for the second quarter of 2024.In...
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
In-licensed SYN-2510/IMM2510, a potentially best-in-class PD-L1xVEGF bispecific antibody, and SYN-27M/IMM27M, a next-generation ADCC-enhanced anti-CTLA-4...
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX...
Friday Sector Leaders: General Contractors & Builders, Biotechnology Stocks
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Instil Bio (NASDAQ:TIL) just reported results for the first quarter of 2024.Ins...
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2024
TIL stock results show that Instil Bio missed analyst estimates for earnings per share the first quarter of 2024.
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a...
TIL Stock Earnings: Instil Bio Beats EPS for Q4 2023
TIL stock results show that Instil Bio beat analyst estimates for earnings per share the fourth quarter of 2023.
TIL Stock Earnings: Instil Bio Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Instil Bio (NASDAQ:TIL) just reported results for the fourth quarter of 2023.In...
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a...
Instil Bio stock hits four-month high (NASDAQ:TIL)
Instil Bio (TIL) stock surged 21% on Wednesday after the biotech announced cost-cutting measures and a new partnership for its ITIL-306 program. Read more here.
Instil Bio Announces Strategic Update
Instil Bio Announces Strategic Update
DALLAS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused...
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2023
TIL stock results show that Instil Bio missed analyst estimates for earnings per share the first quarter of 2023.
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Instil Bio (NASDAQ:TIL) just reported results for the first quarter of 2023.Ins...
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2023
TIL stock results show that Instil Bio beat analyst estimates for earnings per share the second quarter of 2023.
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Instil Bio (NASDAQ:TIL) just reported results for the second quarter of 2023.In...
TIL Stock Earnings: Instil Bio Misses EPS for Q3 2023
TIL stock results show that Instil Bio missed analyst estimates for earnings per share the third quarter of 2023.
TIL Stock Earnings: Instil Bio Misses EPS for Q3 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Instil Bio (NASDAQ:TIL) just reported results for the third quarter of 2023.Ins...
Instil Bio announces effective date of 1-for-20 reverse stock split (NASDAQ:TIL)
Instil Bio announces a 1-for-20 reverse stock split effective December 7th, aiming to regain compliance with Nasdaq's minimum bid price requirement.